NBR160

Antibody responses to AZD-1222 immunisation

Infection COVID
  • Lead ResearcherMichelle Linterman, William Foster
  • Study TypeSamples and data
  • InstitutionBabraham Institute
  • Researcher TypeAcademic

Study summary

Vaccines can provide protection against infection and disease through the production of pathogen neutralising antibodies. However, some people are less able to generate effective antibody responses upon immunisation due to their genes. In this study we wish to use the NIHR COVID BioResource to access samples from healthy volunteers immunised with AZD-1222 to compare their antibody responses to people who have known changes in their genes that may contribute to poor antibody responses upon vaccination.

For this study, four serum samples were from men aged 40-50 years of age who were vaccinated with the Oxford AstraZenca COVID-19 vaccine were supplied, in order to compare their antibody responses

Organisation: This study is organised by Dr Michelle Linterman at the Babraham Institute.